Tier 2 — strong

COVFIS-HOME: Home-Based Study to Assess Fisetin in Community-Dwelling Adults With COVID-19

COVFIS-HOME Trial
ClinicalTrials.gov (trial registry record — not yet published in a peer-reviewed journal) 2021 Not applicable — registry record

Bibliography

Trial registry
View on ClinicalTrials.gov Registered trial — results not yet published in a peer-reviewed journal.
Funding
Not disclosed in the ClinicalTrials.gov record.
Competing interests
Not disclosed in the ClinicalTrials.gov record; no results or manuscript are yet available to review for conflicts of interest.

Study snapshot

DesignHome-based interventional trial of oral fisetin in community-dwelling adults with COVID-19 (NCT04771611).
ModelCommunity-dwelling adults with confirmed COVID-19.
SampleActual enrollment: 55 participants
InterventionOral fisetin (dietary supplement) versus comparator per registry protocol.
DurationStudy start 2021-07-14; primary and study completion 2022-09-27; registry results posted by 2023-08-01.
EndpointsCOVID-19 symptom and recovery measures per registered protocol

What the study showed, in plain terms

COVFIS-HOME was a Phase 2 placebo-controlled pilot trial of oral fisetin in at-risk, community-dwelling adults with COVID-19. It extended the senolytic-COVID hypothesis beyond skilled nursing facilities.

The trial is completed. ClinicalTrials.gov reports actual enrollment of 55 participants, study completion on September 27, 2022, and posted registry results. It should no longer be described as recruitment complete with results pending.

Because this was a COVID-19 clinical-outcome trial rather than a dedicated tissue senescence study, it does not by itself establish whether oral fisetin clears senescent cells in human organs.

Key findings

  • Completed Phase 2 placebo-controlled pilot trial with 55 actual participants.
  • Registry results are posted on ClinicalTrials.gov.
  • The study examined COVID-19 complications and safety rather than direct proof of systemic senescent-cell clearance.
  • No peer-reviewed results publication is currently attached to this Biohack Blueprint record.

What this study can and cannot tell us

  • Small pilot sample limits statistical precision and generalizability.
  • The population and clinical context were acute COVID-19, not healthy aging.
  • Registry results should not be treated as equivalent to an independently peer-reviewed full results paper.

Citation network

Articles citing this research paper

4 articles

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability